



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES



Office of Pharmacy Services
Prior Authorization Criteria
Fintepla® (Fenfluramine)
Effective 11/16/2022

[Prior Authorization Request Form](#)

Fintepla is indicated for treatment of seizures associated with Dravet syndrome or **Lennox-Gastaut syndrome** in patients 2 years of age and older.

CRITERIA FOR APPROVAL:

1. The patient has a diagnosis of Dravet Syndrome or **Lennox-Gastaut syndrome**; **AND**
2. The patient must be within the age range as recommended by the FDA label and indication; **AND**
3. Fintepla is prescribed by, or in consultation with a neurologist; **AND**
4. The prescriber, pharmacy, and patient must all be enrolled in the FINTEPLA REMS program; **AND**
5. Documentation of current baseline seizure activity per month must be provided; **AND**
6. For Dravet Syndrome: The patient must have treatment failure/inadequate response to valproate and clobazam. If there is an intolerance, allergy, or contraindication to valproate, one other preferred antiepileptic (such as topiramate or levetiracetam) must be trialed; **AND**
7. For Lennox-Gastaut syndrome: The patient must have treatment failure/inadequate response or intolerance to valproate, lamotrigine and Clobazam, unless contraindicated; **AND**
8. Evaluation with echocardiography **for valvular disease and pulmonary hypertension** is required before treatment, every six months during treatment, and once three to six months after treatment.

Approval Duration: Initial approval will be for 6 months.



**STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES
BUREAU FOR MEDICAL SERVICES**



Criteria for reauthorization:

1. Patient must continue to meet initial approval criteria; **AND**
2. Demonstrate continued documented compliance; **AND**
3. Documented decrease from baseline in seizure frequency per month must be provided.

Continuation of therapy approvals will be granted for 12 months.

References:

- 1.) Fintepla Package Insert
- 2.) Lexi-Comp Clinical Application 5/21, 11/22
- 3.) UptoDate article: Dravet Syndrome management and prognosis accessed 5/21, 11/22